{
    "nct_id": "NCT03815643",
    "official_title": "An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies",
    "inclusion_criteria": "* Participants under enrollment and treatment in an avelumab clinical study under the sponsorship of EMD Serono Research & Development Institute, Inc. / Merck KGaA, Darmstadt, Germany\n\n  * Merck Serono Co., Ltd (Japan)\n* Participants currently enrolled in an avelumab parent study and are on active treatment with avelumab or in long-term survival follow-up after treatment\n* Participants on active treatment must agree to continue to use highly effective contraception (that is, methods with a failure rate of less than 1% per year) for both male and female participants if the risk of conception exists\n* Other protocol defined inclusion criteria could apply.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participants who are pregnant or breastfeeding\n* Participants still on active treatment: Known hypersensitivity to any of the study intervention ingredients\n* Participant has been enrolled in the comparator arm of avelumab parent study\n* Participant has been withdrawn from avelumab parent study for any reason\n* Any other reason that, in the opinion of the Investigator, precludes the participant from participating in the study\n* Other protocol defined exclusion criteria could apply.",
    "miscellaneous_criteria": ""
}